Sertraline in combination with sorafenib: A promising pharmacotherapy to target both depressive disorders and hepatocellular cancer
CitationÖzünal, Z. G., Dönmez Çakıl, Y., Isan, H., Sağlam, E. ve Aktaş, R. G. (2019). Sertraline in combination with sorafenib: A promising pharmacotherapy to target both depressive disorders and hepatocellular cancer. Biologia Futura, SpringerLink. 70, s. 341-348.
Introduction Hepatocellular carcinoma (HCC) is found within the first five most common tumors worldwide. Sorafenib is an approved agent in HCC treatment. Sertraline is a selective serotonin reuptake inhibitor. The aim of the study is to investigate the combination of sertraline and sorafenib at hepatocellular cancer cell proliferation and death. Methods HepG2 cells were treated with drugs and viability test XTT was performed. Cells were stained with hematoxylin and eosin for histological examination or with anti-Bcl-2 antibody and Hoechst 33258 for immunofluorescence. Results Viability results supported dose-dependent antiproliferative effect for both sertraline and sorafenib. Microscopic evaluation of stained cells exerts morphological changes. Discussion This is the first study to show that sorafenib and sertraline have synergistic effect in hepatocellular cancer.
The following license files are associated with this item: